BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524516

BACPHAR

img img img img
No Data Available

BACIL PHARMA LTD. Share Price Update

As of the latest trading session, BACIL PHARMA LTD. share price is currently at ₹ 40.09, which is up by ₹ 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 38.09 and ₹ 41.89. Over the past year, BACIL PHARMA LTD. has achieved a return of -11.20 %. In the last month alone, the return has been -0.47 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BACIL PHARMA LTD. fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    57.50

  • P/E Ratio (TTM)

    91.11

  • Beta

    0.15

  • Book Value / share

    18.62

  • Return on equity

    -0.98%

  • EPS (TTM)

    0.44

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.01

info icon alternate text

BACIL PHARMA LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.04
Net Profit 0.01
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.01
EBITDA 0.02
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.11
Net Profit 0.67
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.48
EBITDA 0.89
Effective Tax Rate (%) 24.71
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.07
Net Profit 0.02
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.03
EBITDA 0.02
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.06
Net Profit -0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.10
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.07
Net Profit 0.48
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.82
EBITDA 0.49
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.25
Net Profit 0.40
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.69
EBITDA 0.41
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.19
Net Profit -0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.10
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.00
Operating Expense 0.22
Net Profit -0.10
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.17
EBITDA -0.10
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.00
Operating Expense 3.92
Net Profit -3.86
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -6.55
EBITDA -3.86
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 0.00
Operating Expense 0.31
Net Profit -0.24
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.41
EBITDA -0.24
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 18.20
ROE % -0.98
ROCE % -1.04
Total Debt to Total Equity 0.01
EBITDA Margin 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.86
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.05
EBITDA Margin 0.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.68
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.02
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.08
EBITDA Margin 0.00
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2.13
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.13
EBITDA Margin 0.00
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.85
Total Assets 25.60
Total Liabilities 25.60
Total Equity 25.43
Share Outstanding 14353000
Price to Book Ratio 2.33
Return on Assets (%) 1.57
Return on Capital (%) 1.58
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 1.32
Total Liabilities 1.32
Total Equity 1.21
Share Outstanding 5890000
Price to Book Ratio 7.87
Return on Assets (%) -4.45
Return on Capital (%) -4.5
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 1.12
Total Liabilities 1.12
Total Equity 1.09
Share Outstanding 5890000
Price to Book Ratio 3.26
Return on Assets (%) -9.03
Return on Capital (%) -9.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 1.27
Total Liabilities 1.27
Total Equity 1.22
Share Outstanding 5890000
Price to Book Ratio 3.05
Return on Assets (%) -303.54
Return on Capital (%) -306.94
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 4.08
Total Liabilities 4.08
Total Equity 1.39
Share Outstanding 5890000
Price to Book Ratio 1.46
Return on Assets (%) -5.85
Return on Capital (%) -15.27
Particulars MAR 2025 (Values in Cr)
Net Income 0.40
Cash from Operations 0.40
Cash from Investing 0.33
Cash from Financing 2.07
Net change in Cash 2.81
Free Cash Flow 0.40
Particulars MAR 2024 (Values in Cr)
Net Income -0.05
Cash from Operations 0.00
Cash from Investing 0.07
Cash from Financing -0.06
Net change in Cash 0.01
Free Cash Flow 0.00
Particulars MAR 2023 (Values in Cr)
Net Income -0.10
Cash from Operations -0.14
Cash from Investing -0.11
Cash from Financing 0.06
Net change in Cash -0.20
Free Cash Flow -0.14
Particulars MAR 2022 (Values in Cr)
Net Income -3.86
Cash from Operations -4.00
Cash from Investing 3.81
Cash from Financing 0.32
Net change in Cash 0.13
Free Cash Flow -4.00
Particulars MAR 2021 (Values in Cr)
Net Income -0.23
Cash from Operations -0.39
Cash from Investing 0.52
Cash from Financing -0.07
Net change in Cash 0.05
Free Cash Flow -0.39
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.40 13.92 1.47 217.64 28.26 / 68.00
BLISS GVS PHARMA LTD 166.25 16.03 1.55 1757.64 105.05 / 190.65
CIPLA LTD 1530.95 22.73 3.75 123665.73 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 282.65 7.43 2.12 831.87 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2566.65 45.61 25.46 43480.60 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.40 23.09 3.95 217.64 28.26 / 68.00
AMRUTAJAN HEALTH LTD 682.00 34.78 5.76 1971.70 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9048.30 97.85 28.31 22620.75 6301.00 / 10653.05
BLISS GVS PHARMA LTD 166.25 22.44 1.59 1757.64 105.05 / 190.65

BACIL PHARMA LTD. shareholding pattern

Holding

99.91%
0.08%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

BACIL PHARMA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
40.09 0.00 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 39.30
  • 26 Days 36.50
  • 10 Days 37.60
  • 50 Days 37.30
  • 12 Days 37.20
  • 100 Days 38.60
  • 20 Days 36.50
  • 200 Days 37.30
40.20 PIVOT

First Support

38.40

First Resistance

41.89

Second Support

36.71

Second Resistance

43.69

Third Support

34.91

Third Resistance

45.38

RSI

62.54

ADX

31.56

MACD

0.70

Williams % R

-12.48

Commodity Channel Index (CCI)

120.32

Date

2025-11-28

Week

16337.00

Same Day

10505.00

Month

39735.00

1 Year

0.16

3 Year

-0.22

Over 1 Month

-0.47%

down

Over 1 Year

-11.20%

down

Over 3 Months

14.34%

down

Over 3 Years

75.55%

down

Over 6 Months

-3.51%

down

Over 5 Years

47.66%

down

BACIL PHARMA LTD. Corporate Actions

BACIL PHARMA LTD. Share Price

Incorporated as a private limited company in Maharashtra in May '87, Bacil Pharma (BPL) was converted into a public limited company in Oct.'90. The main business activity of the Company is Pharmaceutical.

Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs. Domestic operations are spread across pan India. The company has strong field force of 500 plus, spread over various States and Districts. It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage. To augment the domestic market, Company's operations are based on focused approach.

Multi-Speciality division Vibrant specialises in various specialties, like Anti-Infectives, Pain Management, Respiratory Care, Women's Health, to name a few. Aziwin, Ebay, Balvibe, MNF, Ocium and Monogesic Plus Gel (Innovative Pain Relieving Gel, first time in India) are some of the leading brands in the respective segments. Bal Vedics Division integrates modern medicine with herbal/ayurvedic preparation targeting specific conditions like, Prostrate Enlargement, Renal Calculi, Male Infertility, Women Health etc. Bal Pharma Institutional division is associated with the top Government bodies and Hospitals to extend its product range to the masses. Every area is well covered and supplied through there channel partners.

Bal Pharma Unit - 1, is a finished dosage facility for manufacturing Tablets and Capsules. Bal Pharma Unit - 2, is involved in the manufacturing of APIs. A well-equipped R&D laboratory, a good Kilo laboratory and quality control facilities form the other spheres of activity here. Bal Pharma Unit - 3, is a finished dosage facility for manufacturing Intravenous Fluids, Ophthalmic Preparations & Liquid Oral Preparations.

BPL came out with a public issue of Rs 7 cr in Mar.'94 to set up a plant at Vapi to manufacture bulk drugs like atenalol, norfloxacin, pefloxacin and ciprofloxacin.

The company entered into a marketing arrangement with a distributor Kam Han Industries, Hong Kong, to export 50% of the production. Due to various reasons, the civil works at Vapi were affected. However, to avoid further delay in project implementation, the company acquired from SICOM an existing bulk drug unit with necessary infrastructure and production facilities at Lote Parashuram (near Ratnagiri).

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Bacil Pharma Ltd?

Answer Field

Bacil Pharma Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 40.09 as on Nov 28 2025 03:30 PM.

What is the Market Cap of Bacil Pharma Ltd Share?

Answer Field

The market cap of Bacil Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 57.50 as on Nov 28 2025 03:30 PM.

What is the 52 Week High and Low of Bacil Pharma Ltd?

Answer Field

The 52 Week High and Low of Bacil Pharma Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 62.56 and ₹ 26.69.

What is 1 year return for Bacil Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -11.20%.

What is the P/E Ratio of Bacil Pharma Ltd Share?

Answer Field

As on Nov 28 2025 03:30 PM the price-to-earnings (PE) ratio for Bacil Pharma Ltd share is 91.11.

What is the PB ratio of Bacil Pharma Ltd Share?

Answer Field

As on Nov 28 2025 03:30 PM, the price-to-book (PB) ratio for Bacil Pharma Ltd share is 18.62.

How to Buy Bacil Pharma Ltd Share?

Answer Field

You can trade in Bacil Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Bacil Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Bacil Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Bacil Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59